Metastatic Solid Tumor Clinical Trials in Durham, North Carolina

5 studies are recruiting for metastatic solid tumor in Durham, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Duke University, Durham, North Carolina

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

2. First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

   A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed/refractory, SMARCA4-deficient solid tumors who are intolerant of or have failed available, appro…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Durham, North Carolina

   Locations

   10 in total

   Run by

   Plexium, Inc.

   See if you can join NCT07284186 on ClinicalTrials.gov

3. A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

   Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of neladalkib (NVL-655), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors. Phase 1 will evalu…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Duke University Medical Center, Durham, North Carolina

   Locations

   74 in total

   Run by

   Nuvalent Inc.

   See if you can join NCT05384626 on ClinicalTrials.gov

4. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

   Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Duke Cancer Institute, Durham, North Carolina

   Locations

   21 in total

   Run by

   Clasp Therapeutics, Inc.

   See if you can join NCT06778863 on ClinicalTrials.gov

5. JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

   This Phase 1 first-in-human study will investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of JZP898 monotherapy as well as JZP898 in combination with pembrolizumab in adult participants with advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Duke University Medical Center - Duke Cancer Institute, Durham, North Carolina

   Locations

   10 in total

   Run by

   Jazz Pharmaceuticals

   See if you can join NCT06108050 on ClinicalTrials.gov